---
title: "Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295801707.md"
description: "As of June 30, 2026, the company holds $28.4 million in cash and cash equivalents, ensuring financial stability until mid-2027. Progress has been made in advancing Chemistry, Manufacturing, and Controls (CMC) work towards the NDA resubmission."
datetime: "2026-08-13T12:32:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295801707.md)
  - [en](https://longbridge.com/en/news/295801707.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295801707.md)
---

# Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

As of June 30, 2026, the company holds $28.4 million in cash and cash equivalents, ensuring financial stability until mid-2027. Progress has been made in advancing Chemistry, Manufacturing, and Controls (CMC) work towards the NDA resubmission.

### Related Stocks

- [CING.US](https://longbridge.com/en/quote/CING.US.md)
- [CINGW.US](https://longbridge.com/en/quote/CINGW.US.md)

## Related News & Research

- [Cingulate publishes peer-reviewed pharmacokinetic study of ADHD candidate CTx-1301 in CNS Drugs](https://longbridge.com/en/news/295537403.md)
- [Cingulate Q2 FY26 net loss widens to $5.87 million; SG&A more than doubles to $3.93 million](https://longbridge.com/en/news/295798941.md)
- [Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology](https://longbridge.com/en/news/294366513.md)
- [Commercial Metals Targets $1.8B EBITDA, Expands Construction Solutions Strategy](https://longbridge.com/en/news/294999028.md)
- [CMC Increases Share Repurchase Program By $600 Mln](https://longbridge.com/en/news/294958523.md)